| Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial 2018 · magnesium group · Individuals with metabolic syndrome and hypomagnesemia; age and sex not specified | 382 mg | 16 weeks | 100 |
| Efficacy and safety of oral magnesium supplementation in reducing febrile neutropenia episodes in children with solid tumors treated with cisplatin-based chemotherapy: randomized clinical trial 2020 · magnesium supplement arm · Children aged 9 years or older with solid tumors receiving cisplatin-based chemotherapy | 250 mg | — | 50 |
| A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients 2024 · Magnesium group · Adults aged 18–70 years hospitalized with moderate COVID-19 | 300 mg | 7 days | 30 |
| Magnesium supplementation and perinatal hypoxia: outcome of a parallel group randomised trial in pregnancy 2007 · supplemented group · Black pregnant women of low socioeconomic status, from booking until delivery | 256 mg | — | — |
| Oral magnesium supplementation reduces the incidence of gastrointestinal complications following cardiac surgery: a randomized clinical trial 2017 · intervention group · Patients undergoing coronary artery bypass graft surgery | 800 mg | — | 52 |
| Magnesium hydroxide in ibuprofen tablet reduces the gastric mucosal tolerability of ibuprofen 2004 · magnesium hydroxide-containing formulation (buffered ibuprofen) · healthy men | 600 mg | 5 days | 20 |
| Effect of magnesium and vitamin B6 supplementation on mental health and quality of life in stressed healthy adults: Post-hoc analysis of a randomised controlled trial 2021 · Magnesium alone · Adults aged 18–50 with moderate to extremely severe stress and suboptimal serum magnesium levels | 300 mg | 8 weeks | 132 |
| A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps 2021 · MOMH group · Men and women aged 45 years or older with diagnosed nocturnal leg cramps, including at least four episodes during screening | 226 mg | 60 days | 95 |
| Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial 2014 · treatment group · Healthy women with a mean age of 71.5 years attending a mild fitness program | 300 mg | 12 weeks | 62 |
| Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep 2010 · magnesium group · Adults aged 51–85 years with poor sleep quality (PSQI score higher than five) | 320 mg | 7 weeks | 50 |
| Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm) 2004 · group A (magnesium supplemented) · People with type 1 diabetes and chronic magnesium depletion | 300 mg | 5 years | 49 |
| A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study 2000 · 200 mg Mg · Women with mild premenstrual symptoms, average age 32 years | 200 mg | — | 44 |
| Oral magnesium for relief in pregnancy-induced leg cramps: a randomised controlled trial 2015 · magnesium bisglycinate chelate · Pregnant women, 14–34 weeks of gestation, with leg cramps at least twice per week | 300 mg | 4 weeks | 41 |
| Magnesium Supplementation and the Effects on Wound Healing and Metabolic Status in Patients with Diabetic Foot Ulcer: a Randomized, Double-Blind, Placebo-Controlled Trial 2018 · magnesium group · People with grade 3 diabetic foot ulcers; age and sex not reported | 250 mg | 12 weeks | 35 |
| The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: a randomized clinical trial 2022 · magnesium group · Women aged 18–45 with polycystic ovary syndrome (PCOS), referred for infertility care | 250 mg | 10 weeks | 32 |
| Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms 2022 · magnesium group · Obese women with mild to moderate depressive symptoms | 250 mg | 8 weeks | 27 |
| Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial 2022 · Magnesium intervention · People aged 15–50 with restless legs syndrome, excluding those with specified risk factors; sex not restricted | 250 mg | 60 days | 25 |
| Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial 2012 · magnesium · Children and adolescents aged 7–19 years with cystic fibrosis | 300 mg | 8 weeks | 22 |
| Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial 2007 · magnesium · Children and adolescents aged 7–19 years with moderate persistent asthma | 300 mg | 60 days | 18 |
| Investigation of the effect of short-term change in dietary magnesium intake in asthma 1997 · magnesium treatment period · Adults with asthma; age and sex not specified | 400 mg | 3 weeks | 17 |
| Magnesium Supplementation Modulates T-cell Function in People with Type 2 Diabetes and Low Serum Magnesium Levels 2024 · magnesium · Adults with insulin-treated type 2 diabetes and low serum magnesium levels; mean age 67 years, 7 males among 12 included participants | 360 mg | 6 weeks | 12 |
| The effect of acute vs chronic magnesium supplementation on exercise and recovery on resistance exercise, blood pressure and total peripheral resistance on normotensive adults 2015 · chronic magnesium intervention · Recreationally active adults, 40.8 ± 4.4 years on average; 4 males and 3 females; normotensive | 300 mg | 4 weeks | 7 |
| The effect of acute vs chronic magnesium supplementation on exercise and recovery on resistance exercise, blood pressure and total peripheral resistance on normotensive adults 2015 · acute magnesium intervention · Recreationally active adults, 35.8 ± 6.2 years on average; 3 males and 3 females; normotensive | 300 mg | 7 days | 6 |
| Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial 2010 · Mg group · Men and women aged 21–55 with mild-to-moderate asthma | 340 mg | 198 days | — |
| Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial 2016 · magnesium · Overweight and slightly obese adults; 30 men and 22 postmenopausal women, mean age 62 ± 6 years | 351 mg | 24 weeks | — |
| Ca:Mg Ratio, APOE Cytosine Modifications, and Cognitive Function: Results from a Randomized Trial 2020 · Magnesium treatment arm · Adults aged 40–85 with dietary calcium intake of at least 700 mg/day and a Ca:Mg intake ratio of at least 2.6; many had previously diagnosed colorectal adenomas or hyperplastic polyps. | 217 mg | 12 weeks | — |
| Effects of Magnesium Supplementation on Muscle Soreness and Performance 2022 · magnesium group · College-aged men and women | 350 mg | 10 days | — |
| Magnesium supplementation alleviates premenstrual symptoms of fluid retention 1998 · Magnesium supplementation · Women with premenstrual symptoms | 200 mg | — | — |
| Effect of dietary magnesium supplementation in the prevention of coronary heart disease and sudden cardiac death 1990 · Group A (magnesium-rich diet) · High-risk individuals aged 25–63 years, mostly male, with cardiovascular risk factors or coronary disease | 1.14 g | 10 years | 206 |
| [Oral low-dose magnesium gluconate preventing pregnancy induced hypertension] 1997 · treatment group 2 · Pregnant women at high risk of pregnancy-induced hypertension; age and gestational details beyond starting at week 28 are not reported | 3 g | — | 29 |
| [Oral low-dose magnesium gluconate preventing pregnancy induced hypertension] 1997 · treatment group 1 · Pregnant women at high risk of pregnancy-induced hypertension; age and gestational details beyond starting at week 28 are not reported | 3 g | — | 22 |
| The role of gastric acid and Helicobacter pylori in the natural course of duodenal ulcer 1999 · Group C · Patients with H. pylori-positive duodenal ulcers; age and sex not reported | 80 mL | 8 weeks | — |
| The role of gastric acid and Helicobacter pylori in the natural course of duodenal ulcer 1999 · Group D · Patients with H. pylori-positive duodenal ulcers; age and sex not reported | 80 mL | 8 weeks | — |
| [Magnesium, calcium, hemoglobin, hematocrit, estriol and human placental lactogen with magnesium substitution in pregnancy] 1990 · magnesium group · Pregnant women; age and specific condition not stated | 15 mmol | — | — |
| Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction 1993 · magnesium treatment · Adults aged 31–92 who survived an acute myocardial infarction | 15 mmol | 1 year | — |
| Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial 2021 · C (magnesium) · Adults aged 18–65 with diagnosed migraine and at least four monthly attacks | 500 mg | 12 weeks | 86 |
| Effects of magnesium and potassium supplementation on insomnia and sleep hormones in patients with diabetes mellitus 2024 · T2: Magnesium · Men and women aged 19–65 with diabetes and insomnia | 500 mg | 60 days | 75 |
| A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study 2000 · 200 mg Mg + 50 mg vitamin B6 · Women with mild premenstrual symptoms, average age 32 years | 200 mg | — | 44 |
| [Magnesium in migraine. Results of a multicenter pilot study] 1994 · magnesium · 43 migraine patients meeting International Headache Society criteria | 600 mg | — | 43 |
| The effect of preoperative oral magnesium oxide on the severity of postoperative pain among women undergoing hysterectomy 2022 · magnesium oxide group · Women undergoing hysterectomy; age range and health conditions beyond the surgical indication not reported | 500 mg | 1 day | 32 |
| The effects of magnesium prophylaxis in migraine without aura 2008 · magnesium treatment group · Adults aged 20–55 with migraine without aura and 2–5 migraine attacks per month | 600 mg | 90 days | 30 |
| Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: A randomized, double-blind, placebo-controlled trial 2017 · magnesium group (MG) · depressed people with magnesium deficiency | 500 mg | 8 weeks | 30 |
| The Effect of Oral Magnesium Supplement on Postoperative Pain Following Mandibular Third Molar Surgery: A Split-Mouth Randomized Placebo-Controlled Trial 2025 · magnesium · Healthy adults aged 18 years or older, both sexes, undergoing bilateral mandibular third molar surgery | 500 mg | 3 days | 25 |
| Short-Term Magnesium Supplementation Has Modest Detrimental Effects on Cycle Ergometer Exercise Performance and Skeletal Muscle Mitochondria and Negligible Effects on the Gut Microbiota: A Randomized Crossover Clinical Trial 2025 · magnesium chloride · Healthy men and women aged 18–40 who regularly exercised or had a history of competitive cycling; not diagnosed with hypomagnesemia | 600 mg | 9 days | 15 |
| Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial 2008 · MgCl2 group · Elderly patients with newly diagnosed depression, type 2 diabetes, and hypomagnesemia | 450 mg | 12 weeks | — |
| The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis 2012 · magnesium oxide · patients with migraine | 500 mg | 12 weeks | — |
| North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes 2015 · 800 mg daily magnesium oxide group · Postmenopausal women with a history of breast cancer and bothersome hot flashes | 800 mg | 8 weeks | — |
| The effects of magnesium supplementation on serum level of brain derived neurotrophic factor (BDNF) and depression status in patients with depression 2021 · magnesium (MG) group · people with depression | 500 mg | 8 weeks | — |
| Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study 1996 · magnesium group · Adults aged 18–65 years with migraine according to International Headache Society criteria | 600 mg | 12 weeks | — |
| Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial 2022 · Magnesium-supplemented group · Adults aged 18–65 with prediabetes who were first-degree relatives of people with type 2 diabetes; predominantly women | 250 mg | 12 weeks | 34 |
| Magnesium Sulfate Administration in Moderate Coronary Artery Disease Patients Improves Atherosclerotic Risk Factors: A Double-Blind Clinical Trial Study 2020 · Mg-treated · Patients with moderate coronary artery disease | 300 mg | 26 weeks | 32 |
| Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabetics 1994 · sustained-release magnesium chloride · Adults aged 28–84 with non-insulin-dependent diabetes mellitus and serum cholesterol over 5.20 mmol/L | 384 mg | 6 weeks | 28 |
| The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients 2018 · Mg group · Men and women aged 35–60 with newly diagnosed type 2 diabetes, treated with antidiabetic drugs | 250 mg | 90 days | 20 |
| Magnesium citrate supplementation decreased blood pressure and HbA1c in normomagnesemic subjects with metabolic syndrome: a 12-week, placebo-controlled, double-blinded pilot trial 2021 · Mg supplemented group · Normomagnesemic individuals with metabolic syndrome; age and sex not reported | 400 mg | 12 weeks | 13 |
| Bone and vascular effects of magnesium supplements in CKD patients (the MagicalBone Pilot Study) 2024 · intervention group · Patients with CKD stages 3–4; age and sex not reported | 360 mg | 456 days | 7 |
| Magnesium supplementation to prevent high blood pressure in pregnancy: a randomised placebo control trial 2013 · magnesium-supplemented group · Pregnant primigravida women; age not stated | 300 mg | — | — |
| Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial 2014 · intervention group · Metabolically obese, normal-weight individuals with hypomagnesemia | 382 mg | 120 days | — |
| EFFECT OF MAGNESIUM L-LACTATE SUPPLEMENT ON BLOOD PRESSURE AND CORRECTED QT INTERVAL IN A SAMPLE OF IRAQI WOMEN WITH METABOLIC SYNDROME 2023 · magnesium L-lactate · Women diagnosed with metabolic syndrome | 168 mg | — | — |
| Effect of prophylactic bisoprolol plus magnesium on the incidence of atrial fibrillation after coronary bypass surgery: results of a randomized controlled trial 2006 · prophylaxis group · Adults undergoing elective on-pump CABG surgery, age 65 ± 8 years on average, with no prior atrial fibrillation | 1.8 g | 7 days | 50 |
| A Randomized Trial Comparing the Bowel Cleansing Efficacy of Sodium Picosulfate/Magnesium Citrate and Polyethylene Glycol/Bisacodyl (The Bowklean Study) 2020 · Bowklean · Taiwanese outpatients undergoing colonoscopy; age and sex range not specified | 3.5 g | 2 days | 316 |
| Mechanical colon cleansing for screening colonoscopy: A randomized controlled trial 2017 · PIE group · Outpatients at a VA hospital undergoing screening colonoscopy; mean age 62 years, 75% men | 296 mL | 1 day | 135 |
| Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial 2018 · Mg alone · Adults aged 18–50 with moderate to extremely severe stress and suboptimal serum magnesium concentrations | 1.4 g | 8 weeks | 132 |
| Effect of magnesium and vitamin B6 supplementation on mental health and quality of life in stressed healthy adults: Post-hoc analysis of a randomised controlled trial 2021 · Magnesium + vitamin B6 · Adults aged 18–50 with moderate to extremely severe stress and suboptimal serum magnesium levels | 300 mg | 8 weeks | 132 |
| Role of magnesium supplementation in the treatment of depression: A randomized clinical trial 2017 · Magnesium treatment period (immediate or delayed) · Adults aged 18 years or older with mild-to-moderate depression | 2 g | 6 weeks | 112 |
| Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease 2003 · oral magnesium · Men and women aged 42–83 with coronary artery disease | 30 mmol | 26 weeks | 94 |
| Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial 2021 · B (sodium valproate + magnesium) · Adults aged 18–65 with diagnosed migraine and at least four monthly attacks | 500 mg | 12 weeks | 86 |
| Efficacy and safety of a magnesium sulfate-rich natural mineral water for patients with functional constipation 2014 · Hépar 0.5 group · Women aged 18–60 years with functional constipation | 500 mL | 4 weeks | 85 |
| Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial 2003 · magnesium oxide · Children aged 3–17 years with frequent moderate-to-severe migrainous headache | 9 mg/kg | 16 weeks | 58 |
| Late outcome of a randomized study on oral magnesium for premature complexes 2014 · MgP group, first treatment · Adults with symptomatic premature ventricular or supraventricular complexes and structurally normal hearts | 3 g | 30 days | 45 |
| [New approaches to the treatment of patients with idiopathic mitral valve prolapse] 2000 · study group · Patients with idiopathic mitral valve prolapse; age and sex not stated | 3 g | 26 weeks | 43 |
| Impact of Preoperative Calcium and Magnesium Supplementation on Quality of Life and Hypocalcemia Post-Thyroidectomy 2026 · Intervention group A · Adults aged 20–70 with Graves’ disease or nodular goitre undergoing thyroidectomy | 375 mg | 2 weeks | 40 |
| Comparison of adding magnesium sulfate, dexmedetomidine and ondansetron to lidocaine for gargling before laryngoscopy and endotracheal intubation to prevent sore throat: a randomized clinical trial 2024 · magnesium sulfate group · Adults aged 30–60 years, ASA class I–II, undergoing general anesthesia with laryngoscopy and endotracheal intubation | 2 g | 1 day | 35 |
| Successful improvement of frequency and symptoms of premature complexes after oral magnesium administration 2012 · MgP group · Symptomatic patients aged 16–70 with more than 240 premature ventricular or supraventricular complexes on 24-hour Holter monitoring and no structural heart disease or renal failure | 3 g | 30 days | 30 |
| The Effects of Magnesium and Vitamin E Co-Supplementation on Hormonal Status and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome 2019 · magnesium plus vitamin E supplements · Women aged 18–40 years with polycystic ovary syndrome | 250 mg | 12 weeks | 30 |
| Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients 2006 · oral magnesium · Men with stable coronary artery disease; mean age 61 years | 30 mmol | 26 weeks | 28 |
| Oral magnesium therapy improves endothelial function in patients with coronary artery disease 2000 · magnesium · Adults aged 42–82 with stable coronary artery disease; 41 men and 9 women enrolled overall | 30 mmol | 26 weeks | 25 |
| Magnesium ions and barium coating of colonic mucosa: is it a simple question of viscosity? 2001 · G1 magnesium members · Patients scheduled for double-contrast barium enema; age and sex not reported. | 1 g | 1 day | 23 |
| Magnesium ions and barium coating of colonic mucosa: is it a simple question of viscosity? 2001 · G2 magnesium members · Patients scheduled for double-contrast barium enema; age and sex not reported. | 2 g | 1 day | 23 |
| Magnesium ions and barium coating of colonic mucosa: is it a simple question of viscosity? 2001 · G3 magnesium members · Patients scheduled for double-contrast barium enema; age and sex not reported. | 3 g | 1 day | 23 |
| The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial 2011 · supplemented group · Long-term care facility residents with primary insomnia; mean age 78.3 ± 3.9 years; sex not reported | 225 mg | 8 weeks | 22 |
| Late outcome of a randomized study on oral magnesium for premature complexes 2014 · MgP crossing-over group · Adults with symptomatic premature complexes who had initially received placebo and remained symptomatic | 3 g | 30 days | 21 |
| Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial 2020 · Group C · Children aged over 6 months and under 6 years with functional constipation | 30 mg/kg | 4 weeks | 21 |
| Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation 2007 · MgO · Children under 10 years old with chronic constipation | 50 mg/kg | 4 weeks | 18 |
| Late outcome of a randomized study on oral magnesium for premature complexes 2014 · MgP retreatment after relapse · Adults with symptomatic premature complexes who relapsed after initially receiving MgP | 3 g | 30 days | 17 |
| [Therapeutic effects of magnesium in dysmenorrhea] 1990 · magnesium · Women aged 16–42 with primary dysmenorrhea | 15 mmol | — | 11 |
| Magnesium hydroxide: new insights into the mechanism of its laxative effect and the potential involvement of prostaglandin E2 1992 · 1,200 mg Mg(OH)2 · Volunteers older than 55 years with normal bowel habits | 1.2 g | 5 days | 6 |
| Magnesium hydroxide: new insights into the mechanism of its laxative effect and the potential involvement of prostaglandin E2 1992 · 2,400 mg Mg(OH)2 · Volunteers older than 55 years with normal bowel habits | 2.4 g | 5 days | 6 |
| Magnesium hydroxide: new insights into the mechanism of its laxative effect and the potential involvement of prostaglandin E2 1992 · 3,600 mg Mg(OH)2 · Volunteers older than 55 years with normal bowel habits | 3.6 g | 5 days | 6 |
| Oral magnesium successfully relieves premenstrual mood changes 1991 · Mg · Women aged 24–39 with premenstrual syndrome | 1.08 g | — | — |
| Magnesium pidolate in the treatment of seasonal allergic rhinitis. Preliminary data 1990 · Mg pidolate (MAG2) · People with seasonal allergic rhinitis (hay fever); age and sex not reported | 4.5 g | 30 days | — |
| The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis 2012 · Mg-L-carnitine · patients with migraine | 500 mg | 12 weeks | — |
| Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study 2014 · CVS Antacid Supreme · Adults with GERD symptoms and a history of LA A or B esophagitis and/or abnormal pH monitoring | 135 mg | 1 day | — |
| Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial 2021 · MgO group · Adults with chronic idiopathic constipation; mean age 42 years, 93% women | 1.5 g | 4 weeks | — |
| Short-Term Magnesium Therapy Alleviates Moderate Stress in Patients with Fibromyalgia: A Randomized Double-Blind Clinical Trial 2022 · Mg group · Adults over 18 years with diagnosed fibromyalgia and a DASS-42 stress score over 18 | 50 mg | 4 weeks | — |
| Oral magnesium intake reduces permanent hearing loss induced by noise exposure 1994 · magnesium group · Young, healthy, normal-hearing recruits undergoing basic military training and exposed to hazardous noise | 6.7 mmol | 60 days | — |
| Oral magnesium supplementation as prophylaxis for noise-induced hearing loss: results of a double blind field study 1993 · Magnesium group · voluntary military recruits with normal hearing undergoing military training; age and sex not specified | 4 g | 60 days | — |
| Prospective, randomized, controlled comparison of the use of polyethylene glycol electrolyte lavage solution in four-liter versus two-liter volumes and pretreatment with either magnesium citrate or bisacodyl for colonoscopy preparation 1998 · Prep 2: 2 L PEG-ELS plus magnesium citrate · Outpatients undergoing colonoscopy; mostly men (148 of 150); age and condition not specified | 296 mL | 1 day | — |
| On the significance of magnesium in extreme physical stress 1998 · Mg-orotate group · Competitive triathletes; age and sex not reported | 17 mmol | 4 weeks | — |
| Effect of magnesium L-lactate on blood pressure in patients with an implantable cardioverter defibrillator 2009 · magnesium L-lactate · Patients with implanted cardioverter defibrillators (ICDs) | 504 mg | 24 weeks | 25 |
| The impact of vitamins and/or mineral supplementation on blood pressure in type 2 diabetes 2004 · group M · People with type 2 diabetes; age and sex not reported | 200 mg | 90 days | 16 |
| Effects of magnesium on blood pressure and intracellular ion levels of Brazilian hypertensive patients 1996 · Magnesium · Adults aged 36–65 with uncomplicated mild to moderate primary hypertension | 600 mg | 6 weeks | 15 |
| Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women 2017 · magnesium group · Women aged 40–65 with hypertension treated with hydrochlorothiazide and mean 24-hour blood pressure at least 130/80 mmHg | 600 mg | 26 weeks | — |
| Magnesium and ascorbic acid supplementation in diabetes mellitus 1995 · Mg supplementation · Outpatients with diabetes mellitus; results reported separately for insulin-dependent and non-insulin-dependent diabetes mellitus | 600 mg | 90 days | — |
| Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial 2015 · Verum (investigational nutritional product) · Adults aged 18–65 of either sex with migraine with or without aura, and at least 3 migraine attacks per month before recruitment | 600 mg | 90 days | 63 |
| Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation 2011 · Group MV · Patients with type 2 diabetes | 250 mg | 120 days | — |
| A randomized, controlled trial of oral sulfate solution versus polyethylene glycol for bowel preparation for colonoscopy 2025 · Group A (OSS) · Men and women aged 18–70 years undergoing screening, surveillance, or diagnostic colonoscopy | 1.6 g | 1 day | 324 |
| Sodium Picosulfate with Magnesium Citrate (SPMC) Plus Laxative Is a Good Alternative to Conventional Large Volume Polyethylene Glycol in Bowel Preparation: A Multicenter Randomized Single-Blinded Trial 2015 · SPMC/bisacodyl group · Adults aged 20–75 undergoing elective daytime outpatient colonoscopy | 7 g | 1 day | 181 |
| Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial 2018 · Mg–vitamin B6 combination · Adults aged 18–50 with moderate to extremely severe stress and suboptimal serum magnesium concentrations | 1.41 g | 8 weeks | 132 |
| Comparison of optimal bowel cleansing effects of 1L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate: A randomized controlled study 2022 · PICO with magnesium citrate group · Adults aged 19–75 undergoing colonoscopy | 340 mL | 1 day | 113 |
| Magnesium citrate with a single dose of sodium phosphate for colonoscopy bowel preparation 2011 · Group II · Patients undergoing colonoscopy; age and sex not specified | 250 mL | 2 days | 80 |
| Effects of magnesium and potassium supplementation on insomnia and sleep hormones in patients with diabetes mellitus 2024 · T4: Magnesium + potassium · Men and women aged 19–65 with diabetes and insomnia | 500 mg | 60 days | 73 |
| Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population. A pilot study. The Ichilov Magnesium Study Group 1994 · M2 · Adults with successful percutaneous transluminal coronary angioplasty; age and sex not stated | 600 mg | 26 weeks | 49 |
| The effect of vitamin D and magnesium supplementation on the mental health status of attention-deficit hyperactive children: a randomized controlled trial 2021 · Intervention group · Children aged 6–12 years with ADHD and low serum 25-hydroxyvitamin D and magnesium levels | 6 mg/kg | 8 weeks | 33 |
| The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial 2019 · magnesium plus vitamin E · Patients with grade 3 diabetic foot ulcer | 250 mg | 12 weeks | 29 |
| Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms 2022 · co-supplementation group · Obese women with mild to moderate depressive symptoms | 250 mg | 8 weeks | 27 |
| Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial 2020 · Group B · Children aged over 6 months and under 6 years with functional constipation | 30 mg/kg | 4 weeks | 19 |
| Magnesium-creatine supplementation effects on body water 2003 · MgO-Cre · 35 subjects; age, sex, and health condition not specified | 800 mg | 2 weeks | — |
| Magnesium-creatine supplementation effects on body water 2003 · MgC-Cre · 35 subjects; age, sex, and health condition not specified | 800 mg | 2 weeks | — |
| A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial 2004 · active combination · Patients with migraine; age and sex not reported | 300 mg | 90 days | — |
| A randomized controlled trial of four precolonoscopy bowel cleansing regimens 2011 · Two sachets PSMC plus magnesium citrate (M) · Patients undergoing outpatient colonoscopy; age and sex not reported | 300 mL | 1 day | — |
| Randomized Study of the Effects of Vitamin D and Magnesium Co-Supplementation on Muscle Strength and Function, Body Composition, and Inflammation in Vitamin D-Deficient Middle-Aged Women 2021 · intervention · Women aged 40–55 years with vitamin D deficiency | 250 mg | 8 weeks | — |
| Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators 1997 · active therapy · Patients with frequent ventricular arrhythmias (>720 ventricular premature beats per 24 hours); age and sex not specified | 6 mmol | 3 weeks | — |
| Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures 1998 · magnesium supplementation period · Adults aged 33–74 with essential hypertension and office BP >140/90 mm Hg; untreated or treated | 20 mmol | 8 weeks | 60 |
| Nutritional magnesium supplementation does not change blood pressure nor serum or muscle potassium and magnesium in untreated hypertension. A double-blind crossover study 1994 · magnesium treatment · Adults aged 20–59 with untreated mild-to-moderate hypertension | 15 mmol | 60 days | 39 |
| The effect of magnesium supplementation on biochemical markers of bone metabolism or blood pressure in healthy young adult females 1999 · Self-selected diet with magnesium supplement · Healthy normotensive adult females aged 20–28 years | 10 mmol | 4 weeks | 26 |
| Blood pressure response during long-term treatment with magnesium is dependent on magnesium status. A double-blind, placebo-controlled study in essential hypertension and in subjects with high-normal blood pressure 1991 · magnesium group · People with mild essential hypertension or high-normal blood pressure; age and sex not reported | 15 mmol | 26 weeks | — |
| Nutritional dose of magnesium in hypertensive patients on beta blockers lowers systolic blood pressure: a double-blind, cross-over study 1994 · magnesium aspartate · Adults aged 26–69 years with moderate essential hypertension treated with beta blockers | 15 mmol | 8 weeks | — |
| Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension 1994 · magnesium aspartate-HCl group · Middle-aged and elderly women with mild to moderate hypertension who were not taking antihypertensive medication | 20 mmol | 26 weeks | — |
| Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake 1998 · magnesium · Normotensive women, mean age 39, with low habitual intake of potassium, calcium, and magnesium | 14 mmol | 16 weeks | — |
| Impact of magnesium supplementation, in combination with vitamin B6, on stress and magnesium status: secondary data from a randomized controlled trial 2020 · Magnesium · Adults with stress; the erythrocyte-magnesium subgroup analysis included participants with low baseline erythrocyte magnesium (<1.6 mmol/L). | 300 mg | 8 weeks | 132 |
| Comparison of magnesium status using X-ray dispersion analysis following magnesium oxide and magnesium citrate treatment of healthy subjects 2012 · magnesium citrate · Healthy volunteers, 31–75 years, with no apparent heart disease; women and men | 296 mg | 30 days | 41 |
| Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPE(TM) Microcapsules) Versus Other Magnesium Sources 2024 · MAGSHAPE microcapsules (Mg-MS) · Healthy men and women aged 20–55 years with normal plasma magnesium levels | 375 mg | 1 day | 40 |
| Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPE(TM) Microcapsules) Versus Other Magnesium Sources 2024 · Magnesium oxide (MgO) · Healthy men and women aged 20–55 years with normal plasma magnesium levels | 375 mg | 1 day | 40 |
| Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPE(TM) Microcapsules) Versus Other Magnesium Sources 2024 · Magnesium citrate (Mg-C) · Healthy men and women aged 20–55 years with normal plasma magnesium levels | 375 mg | 1 day | 40 |
| Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPE(TM) Microcapsules) Versus Other Magnesium Sources 2024 · Magnesium bisglycinate (Mg-BG) · Healthy men and women aged 20–55 years with normal plasma magnesium levels | 375 mg | 1 day | 40 |
| Circulating Ionized Magnesium: Comparisons with Circulating Total Magnesium and the Response to Magnesium Supplementation in a Randomized Controlled Trial 2020 · Magnesium group · Relatively healthy adults aged over 55 years with no prior history of cardiovascular disease | 400 mg | 10 weeks | 29 |
| Positive effects of magnesium supplementation in metabolic syndrome 2024 · magnesium-treated group · Adults aged 60.2 ± 12.5 years with metabolic syndrome; 13 male and 14 female | 400 mg | 12 weeks | 27 |
| Circulating Ionized Magnesium as a Measure of Supplement Bioavailability: Results from a Pilot Study for Randomized Clinical Trial 2020 · magnesium chloride (ReMag®) · Healthy men and women aged 18–65 years | 300 mg | 1 day | 17 |
| Assessment of bioavailability of Mg from Mg citrate and Mg oxide by measuring urinary excretion in Mg-saturated subjects 2019 · magnesium citrate (MgC) · 14 healthy males | 400 mg | 1 day | 14 |
| Assessment of bioavailability of Mg from Mg citrate and Mg oxide by measuring urinary excretion in Mg-saturated subjects 2019 · magnesium oxide (MgO) · 14 healthy males | 400 mg | 1 day | 14 |
| Moderate magnesium deprivation results in calcium retention and altered potassium and phosphorus excretion by postmenopausal women 2007 · Basal diet supplemented with magnesium · Postmenopausal women aged 49–71 years | 220 mg | 72 days | 11 |
| Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study 2003 · magnesium amino-acid chelate · healthy individuals; age and sex not reported | 300 mg | 60 days | — |
| Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study 2003 · magnesium citrate · healthy individuals; age and sex not reported | 300 mg | 60 days | — |
| Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study 2003 · magnesium oxide · healthy individuals; age and sex not reported | 300 mg | 60 days | — |
| Urinary magnesium excretion in asthmatic children receiving magnesium supplementation: a randomized, placebo-controlled, double-blind study 2003 · Magnesium citrate, children aged 7 years or younger · Children aged 4–7 years with mild or moderate persistent bronchial asthma | 200 mg | 12 weeks | — |
| Urinary magnesium excretion in asthmatic children receiving magnesium supplementation: a randomized, placebo-controlled, double-blind study 2003 · Magnesium citrate, children older than 7 years · Children older than 7 years through age 16 with mild or moderate persistent bronchial asthma | 290 mg | 12 weeks | — |
| Magnesium status and the physical performance of volleyball players: effects of magnesium supplementation 2014 · experimental group · Professional male volleyball players who were not magnesium-deficient | 350 mg | 4 weeks | — |
| Is magnesium content in erythrocytes suitable for evaluating cation retention after oral physiological supplementation in marginally magnesium-deficient subjects? 1993 · magnesium supplementation · healthy, marginally magnesium-deficient subjects; age and sex not stated | 366 mg | 8 weeks | — |
| Effect of a Combination of Magnesium, B Vitamins, Rhodiola, and Green Tea (L-Theanine) on Chronically Stressed Healthy Individuals-A Randomized, Placebo-Controlled Study 2022 · Mg-Teadiola · Adults aged 18–65, either sex, otherwise healthy and chronically stressed (DASS-42 stress score ≥14) | 150 mg | 4 weeks | 51 |
| A Magtein(®), Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults 2022 · Magtein®PS group · Healthy Chinese adults aged 18–65 years, men and women | 1.6 g | 30 days | 51 |
| Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause 2006 · ES (Estromineral serena) · Symptomatic menopausal women with sleep or mood alterations | 50 mg | 24 weeks | 44 |
| Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: A randomised, double-blind, placebo-controlled, crossover trial 2025 · herbal supplement · Adults aged 18–75, male and female, otherwise healthy and self-reporting stress (PSS score ≥13) | 113 mg | 15 days | 35 |
| Increased vitamin plasma levels in Swedish military personnel treated with nutrients prior to automatic weapon training 2011 · Nutrients (active treatment) · Normally hearing Swedish military personnel, officers and military academy trainees, ages 18 and older, undergoing weapons training | 1.95 g | 2 days | 31 |
| Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial 2018 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS); age not reported | 200 mg | 12 weeks | 30 |
| A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial 2024 · experimental formula · Adults aged 55–85 with sarcopenia | 300 mg | 120 days | 30 |
| A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS) 2023 · Active formulation · Exercise-trained adults aged 18–65 in good health who reported exercising at least 3 times weekly for at least 30 minutes per session during the prior year; participants underwent experimental induction of delayed onset muscle soreness. | 840 mg | 4 days | 20 |
| Supportive treatment of vascular dysfunction in pediatric subjects with obesity: the OBELIX study 2022 · Treatment group · Children aged 6–17 years with obesity (BMI above the 95th percentile for age) | 300 mg | 26 weeks | 16 |
| Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation 2011 · Group MVB · Patients with type 2 diabetes | 250 mg | 120 days | — |
| The impact of vitamins and/or mineral supplementation on blood pressure in type 2 diabetes 2004 · group MV · People with type 2 diabetes; age and sex not reported | 200 mg | 90 days | 17 |
| Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2) 2021 · Mg treatment arm · Adults aged 40–85 with adenomas or hyperplastic polyps, or polyp-free individuals at high risk of colorectal cancer; eligible participants had a calcium intake of at least 700 and less than 2000 mg/day and a calcium-to-magnesium intake ratio of at least 2.6 | 206 mg | 12 weeks | 120 |
| Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study 2017 · magnesium group · Hypomagnesemic, obese and pre-diabetic patients with mild-to-moderate chronic kidney disease | 365 mg | 90 days | 57 |
| Natural Magnesium-Enriched Deep-Sea Water Improves Insulin Resistance and the Lipid Profile of Prediabetic Adults: A Randomized, Double-Blinded Crossover Trial 2020 · BDSW group · Adults aged 19–70 with prediabetes, defined by fasting blood glucose of 100–125 mg/dL and 2-hour postprandial glucose of 140–199 mg/dL | 350 mg | 8 weeks | 40 |
| Magnesium from Deep Seawater as a Potentially Effective Natural Product against Insulin Resistance: A Randomized Trial 2024 · test group · Adults aged 19–70 years with impaired glucose tolerance | 350 mg | 12 weeks | 37 |
| Ca:Mg ratio, medium-chain fatty acids, and the gut microbiome 2022 · Mg treatment · Adults aged 40–85 with dietary calcium intake of at least 700 mg/day and below 2000 mg/day, and a dietary Ca:Mg ratio of at least 2.6 | 206 mg | 12 weeks | 34 |
| The effect of magnesium sulfate on gene expression and serum level of inflammatory cytokines in coronary artery disease patients 2023 · MgSO4 group · Patients with moderate coronary artery disease | 300 mg | 90 days | 30 |
| Effects of magnesium supplementation on carotid intima-media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial 2019 · Magnesium group · Diabetic haemodialysis patients | 250 mg | 24 weeks | 27 |
| Long-term magnesium supplementation improves glucocorticoid metabolism: A post-hoc analysis of an intervention trial 2021 · Magnesium group · Men and postmenopausal women aged 45–70 years with BMI 25–35 kg/m², healthy, overweight or slightly obese | 350 mg | 24 weeks | 25 |
| A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls 2006 · Mg-supplemented group · Healthy premenarchal Caucasian girls aged 8–14 with estimated dietary magnesium intake below 220 mg/day | 300 mg | 1 year | 23 |
| Magnesium supplementation affects gene expression related to insulin and lipid in patients with gestational diabetes 2017 · magnesium group · Women aged 18–40 with gestational diabetes who were not taking oral hypoglycemic agents | 250 mg | 6 weeks | 20 |
| The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial 2024 · magnesium oxide supplement group · Women aged 15–35 years with polycystic ovary syndrome (PCOS) | 250 mg | 60 days | 20 |
| The effects of magnesium supplementation on gene expression related to inflammatory markers, vascular endothelial growth factor, and pregnancy outcomes in patients with gestational diabetes 2018 · magnesium oxide · Women aged 18–40 with gestational diabetes mellitus | 250 mg | 6 weeks | 18 |
| Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? 2007 · group A · patients with chronic systolic heart failure | 300 mg | 5 weeks | 17 |
| Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis 2008 · group A (Mg group) · Patients on hemodialysis | 305 mg | 60 days | — |
| Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial 2015 · magnesium group · Men and non-pregnant women aged 30–65 years with hypomagnesaemia and newly diagnosed prediabetes | 382 mg | 120 days | — |
| [Long-term HRV analysis shows stress reduction by magnesium intake] 2016 · group with daily supplementation of 400 mg of magnesium · People with mental and physical stress; age and sex not reported | 400 mg | 90 days | — |
| Effect of magnesium oxide or citrate supplements on metabolic risk factors in kidney stone formers with idiopathic hyperoxaluria: a randomized clinical trial 2024 · MgO group · Adults with calcium stones and idiopathic hyperoxaluria | 360 mg | 8 weeks | — |
| Effect of magnesium oxide or citrate supplements on metabolic risk factors in kidney stone formers with idiopathic hyperoxaluria: a randomized clinical trial 2024 · MgCit group · Adults with calcium stones and idiopathic hyperoxaluria | 360 mg | 8 weeks | — |
| Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study 1990 · potassium with magnesium · Adults with mild hypertension (diastolic blood pressure less than 110 mm Hg) | 20 mmol | 32 weeks | — |
| Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial 2017 · Control · Postmenopausal women with osteopenia; age range not stated | 550 mg | 1 year | — |
| Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake 1998 · all three minerals together · Normotensive women, mean age 39, with low habitual intake of potassium, calcium, and magnesium | 14 mmol | 16 weeks | — |
| Comparison of magnesium status using X-ray dispersion analysis following magnesium oxide and magnesium citrate treatment of healthy subjects 2012 · magnesium oxide · Healthy volunteers, 31–75 years, with no apparent heart disease; women and men | 520 mg | 30 days | 41 |
| Response of Vitamin D after Magnesium Intervention in a Postmenopausal Population from the Province of Granada, Spain 2020 · Magnesium Group (MG) · Postmenopausal women aged 44–76 with low magnesium status and no reported pathology affecting nutritional status | 500 mg | 8 weeks | 27 |
| Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men 2007 · low-dose lactulose (2 g) · 24 healthy adult men | 150 mg | 1 day | 24 |
| Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men 2007 · high-dose lactulose (4 g) · 24 healthy adult men | 150 mg | 1 day | 24 |
| Efficacy of oral magnesium administration on decreased exercise tolerance in a state of chronic sleep deprivation 1998 · Mg group · Healthy volunteers, mean age 21.9 years, undergoing chronic sleep deprivation | 100 mg | 30 days | 8 |
| [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial] 2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported | 80 mg | 1 year | 125 |
| Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year 2018 · intervention · Chinese postmenopausal women in Malaysia; mean age 59 years | 96 mg | 1 year | 61 |
| Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial 2017 · RCE · Postmenopausal women with osteopenia; age range not stated | 550 mg | 1 year | — |
| Comparative Efficacy of Magnesium and Potassium Towards Cholesterol and Quality of Life in Patients With Type 2 Diabetes Mellitus: A Randomised Single-Blinded Controlled Clinical Trial 2024 · Group II (T2) · Adults aged 25–85 with type 2 diabetes mellitus; both sexes | 500 mg | 60 days | 75 |
| Magnesium treatment in alcoholics: a randomized clinical trial 2008 · magnesium treatment group · Adults aged 20–64 with alcohol withdrawal symptoms or elevated serum gamma-glutamyltransferase, following treatment for alcohol withdrawal | 500 mg | 8 weeks | 64 |
| Corticosteroid sparing effects of vitamin C and magnesium in asthma: a randomised trial 2006 · magnesium · Adults with asthma | 450 mg | 10 weeks | 31 |
| The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes 2004 · group M · Adults with type 2 diabetes; age and sex not reported | 200 mg | 90 days | 16 |
| Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes 2005 · group M · Patients with type 2 diabetes; age range and sex not specified | 200 mg | 90 days | 16 |
| Effects of magnesium on postprandial serum lipid responses in healthy human subjects 2010 · fat-with-Mg meal · healthy male volunteers; age not reported | 500 mg | 1 day | 16 |
| The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics 2008 · Rosuvastatin 40 mg plus 20 mL antacid suspension taken simultaneously · Healthy adult male volunteers | 195 mg | 1 day | 14 |
| The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics 2008 · Rosuvastatin 40 mg plus 20 mL antacid suspension taken 2 h after rosuvastatin · Healthy adult male volunteers | 195 mg | 1 day | 14 |
| A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients 2003 · Mg group · Methadone-maintained patients who used illicit opiates and cocaine | 732 mg | 12 weeks | — |
| Acute and chronic oral magnesium supplementation: effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure 2006 · oral magnesium oxide · adults with symptomatic chronic heart failure; age and sex not reported | 800 mg | 90 days | — |
| An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence 2006 · magnesium l-lactate group · Patients receiving sotalol or dofetilide for atrial or ventricular arrhythmias | 504 mg | 2 days | — |
| Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals 2011 · magnesium citrate · Healthy overweight volunteers (BMI ≥25); age and sex not reported | 500 mg | 4 weeks | — |
| Impact of magnesium supplementation, in combination with vitamin B6, on stress and magnesium status: secondary data from a randomized controlled trial 2020 · Magnesium-vitamin B6 · Adults with stress; the erythrocyte-magnesium subgroup analysis included participants with low baseline erythrocyte magnesium (<1.6 mmol/L). | 300 mg | 8 weeks | 132 |
| Prospective Randomized Evaluation of Idiopathic Hyperoxaluria Treatments 2021 · low oxalate diet and supplementation (DS) · Patients with a documented history of calcium oxalate stones and newly diagnosed idiopathic hyperoxaluria | 400 mg | 12 weeks | 55 |
| Prospective Randomized Evaluation of Idiopathic Hyperoxaluria Treatments 2021 · supplementation (S) · Patients with a documented history of calcium oxalate stones and newly diagnosed idiopathic hyperoxaluria | 400 mg | 12 weeks | 47 |
| Comparison of the Efficacy of Oral versus Intravascular Magnesium in the Prevention of Hypomagnesemia and Arrhythmia after CABG 2018 · Oral Mg · Adults with coronary artery disease scheduled for CABG; age and sex range not specified | 1.6 g | 1 day | 36 |
| Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease 1993 · magnesium chloride · Patients with stable congestive heart failure secondary to coronary artery disease, receiving long-term loop diuretics, with normal renal function and low or normal serum magnesium concentrations | 15.8 mmol | 6 weeks | 21 |
| Single Center, Open-Label, Randomized Crossover Trial on Drug-Drug Interactions of Levothyroxine/Magnesium-Citrate and Levothyroxine/Magnesium-Aspartate in Healthy Subjects-The ThyroMag Trial 2025 · Levothyroxine + Magnesium Citrat (LMC) · Healthy female and male volunteers aged 18–65 | 12.4 mmol | 1 day | 15 |
| Single Center, Open-Label, Randomized Crossover Trial on Drug-Drug Interactions of Levothyroxine/Magnesium-Citrate and Levothyroxine/Magnesium-Aspartate in Healthy Subjects-The ThyroMag Trial 2025 · Levothyroxine + Magnesium Aspartat (LMA) · Healthy female and male volunteers aged 18–65 | 10 mmol | 1 day | 15 |
| Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial 1992 · oral magnesium supplementation · Patients treated with cisplatin; age and sex not reported | 6 g | — | 9 |
| An Advanced Formulation of a Magnesium Dietary Supplement Adapted for a Long-Term Use Supplementation Improves Magnesium Bioavailability: In Vitro and Clinical Comparative Studies 2018 · ChronoMag® · 12 normo-magnesemic healthy volunteers; age and sex not specified | 50 mg | 1 day | — |
| Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy 1995 · Magnesium group · Patients with type II diabetes and hypomagnesemia | 30 mmol | 90 days | — |
| Can dietary magnesium modulate lipoprotein metabolism? 1990 · Group A (magnesium-rich diet) · Patients aged 25–63 years; 394 of the 430 study participants were male. Hypomagnesemia was present in a subgroup. | 1.14 g | 12 weeks | 214 |
| Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial 2011 · MgCl(2) group · Non-diabetic, normotensive men and non-diabetic, normotensive, non-pregnant women with serum magnesium levels ≤0·70 mM/L | 2.5 g | 90 days | 54 |
| [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients] 2011 · Group I · Adults aged 29–84 with end-stage renal disease and hyperphosphatemia receiving hemodialysis | 3 g | 12 weeks | 30 |
| The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · Magnesium plus vitamin E · Women aged 18–40 years with polycystic ovary syndrome | 250 mg | 12 weeks | 30 |
| Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial 2008 · MgCO3 group · Adults with end-stage renal disease on maintenance hemodialysis; age range not specified | 1.55 g | 26 weeks | 26 |
| Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers 2006 · linezolid plus antacid · healthy adult men and women | 600 mg | 1 day | 18 |
| Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin 1990 · Magnesium-aluminum hydroxide antacid · 32 subjects; age, sex, and health status not specified | 15 mL | 1 day | 16 |
| Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects 2012 · gabapentin + MgO · healthy adult subjects; age range and sex not stated | 1 g | 1 day | 13 |
| Daily magnesium supplements improve glucose handling in elderly subjects 1992 · chronic magnesium administration (CMA) · Aged subjects, approximately 78 years old, with low erythrocyte magnesium concentration | 4.5 g | 4 weeks | 12 |
| Electrocardiographic changes induced by inhaled salbutamol after treatment with bendrofluazide: effects of replacement therapy with potassium, magnesium and triamterene 1990 · bendrofluazide plus magnesium · 12 normal subjects; age and sex not reported | 24 mmol | 5 days | 12 |
| Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women 2010 · magnesium-supplemented group · Postmenopausal women with osteoporosis | 1.83 g | 30 days | 10 |
| Chronic magnesium administration enhances oxidative glucose metabolism in thiazide treated hypertensive patients 1992 · magnesium · Thiazide-treated hypertensive patients | 15.8 mmol | 8 weeks | 9 |
| Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients 1994 · magnesium supplementation · Elderly, non-obese patients with diet-treated noninsulin-dependent (type II) diabetes | 15.8 mmol | 4 weeks | 9 |
| Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide 1992 · Magnesium hydroxide with tolbutamide · Healthy volunteers | 850 mg | 1 day | 8 |
| Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide 1992 · Magnesium hydroxide with chlorpropamide · Healthy volunteers | 850 mg | 1 day | 8 |
| Enhancement of absorption and effect of glipizide by magnesium hydroxide 1991 · magnesium hydroxide phase · Eight healthy volunteers | 850 mg | 1 day | 8 |
| The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations 1991 · Magnesium hydroxide with micronised glibenclamide · Healthy volunteers; age and sex not reported | 850 mg | 1 day | 7 |
| The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations 1991 · Magnesium hydroxide with non-micronised glibenclamide · Healthy volunteers; age and sex not reported | 850 mg | 1 day | 6 |
| The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac 1991 · magnesium hydroxide phase · Healthy volunteers; age and sex not reported | 850 mg | 1 day | 6 |
| Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial 2004 · magnesium group · Non-diabetic, apparently healthy subjects with insulin resistance and hypomagnesemia | 2.5 g | 90 days | — |
| Contribution of pH to systemic exposure of niflumic acid following oral administration of talniflumate 2011 · Talniflumate with magnesium hydroxide · Healthy volunteers; age and sex not stated | 1 g | 1 day | — |
| Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial 2014 · magnesium chloride · Men and non-pregnant women aged 18–65 with newly diagnosed prediabetes and hypomagnesemia | 30 mL | 90 days | — |
| The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes 1998 · 20.7 mmol Mg group · Adults aged 30–69 with type 2 diabetes, treated by diet or diet plus oral antidiabetic drugs | 20.7 mmol | 30 days | — |
| The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes 1998 · 41.4 mmol Mg group · Adults aged 30–69 with type 2 diabetes, treated by diet or diet plus oral antidiabetic drugs | 41.4 mmol | 30 days | — |
| Liposomal Mineral Absorption: A Randomized Crossover Trial 2022 · Liposomal MVM condition · Healthy adults aged 18–65 years | 22 mg | 1 day | 25 |
| Liposomal Mineral Absorption: A Randomized Crossover Trial 2022 · Standard MVM condition · Healthy adults aged 18–65 years | 23.3 mg | 1 day | 25 |
| Negative balance of calcium and magnesium under relatively low sodium intake in humans 2003 · Relatively low sodium intake with adequate calcium and magnesium intake · Six female students; ages and health status not reported | 280 mg | 10 days | 6 |
| Small bowel absorption of magnesium and calcium sulphate from a natural mineral water in subjects with ileostomy 2006 · High-mineral-content natural mineral water · Six subjects with ileostomy | 2.3 mmol | 2 days | 6 |
| The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial 2022 · magnesium + vitamin D (MagD) · Overweight or obese participants; age and sex not reported | 1.08 g | 12 weeks | — |
| The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes 2004 · group MV · Adults with type 2 diabetes; age and sex not reported | 200 mg | 90 days | 17 |
| Randomized Study of the Effects of Zinc, Vitamin A, and Magnesium Co-supplementation on Thyroid Function, Oxidative Stress, and hs-CRP in Patients with Hypothyroidism 2021 · intervention group · Adults aged 20–65 with hypothyroidism | 250 mg | 10 weeks | 43 |
| Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension 2006 · magnesium potassium supplementation · Patients with essential hypertension; age and sex not reported | 70.8 mg | 4 weeks | 35 |
| Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations 2023 · Non-liposomal multivitamin (NL) · Healthy males and females aged 18–65 years | 22 mg | 1 day | 34 |
| Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations 2023 · Liposomal multivitamin (L) · Healthy males and females aged 18–65 years | 22 mg | 1 day | 34 |
| The Effects of Magnesium and Zinc Co-Supplementation on Biomarkers of Inflammation and Oxidative Stress, and Gene Expression Related to Inflammation in Polycystic Ovary Syndrome: a Randomized Controlled Clinical Trial 2018 · Magnesium and zinc co-supplementation · Women aged 18–40 with polycystic ovary syndrome diagnosed according to the Rotterdam criteria | 500 mg | 12 weeks | 30 |
| The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes 2018 · magnesium plus vitamin E group · Women aged 18–40 with gestational diabetes, non-diabetic before pregnancy | 250 mg | 6 weeks | 30 |
| The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease 2020 · Magnesium plus zinc group · Women aged 40–95 with type 2 diabetes mellitus and proven two- or three-vessel coronary heart disease | 250 mg | 12 weeks | 27 |
| Impact of supplementary high calcium milk with additional magnesium on parathyroid hormone and biochemical markers of bone turnover in postmenopausal women 2002 · milk group · Healthy postmenopausal women | 106 mg | 4 weeks | 25 |
| Fortified whey beverage for improving muscle mass in chronic obstructive pulmonary disease: a single-blind, randomized clinical trial 2020 · intervention group · Men aged 50–70 with moderate-to-severe COPD and BMI below 25 | 275 mg | 8 weeks | 23 |
| Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption 2003 · HCSM with 65.5 mg magnesium · Healthy postmenopausal women | 65.5 mg | 1 day | 21 |
| Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption 2003 · HCSM with 172 mg magnesium · Healthy postmenopausal women | 172 mg | 1 day | 21 |
| Electrocardiographic changes induced by inhaled salbutamol after treatment with bendrofluazide: effects of replacement therapy with potassium, magnesium and triamterene 1990 · bendrofluazide plus potassium plus magnesium · 12 normal subjects; age and sex not reported | 24 mmol | 5 days | 12 |
| Interaction between sotalol and an antacid preparation 1997 · Phase 2: sotalol plus antacid administered together · Six healthy volunteers; age and sex not reported | 1.2 g | 1 day | 6 |
| Interaction between sotalol and an antacid preparation 1997 · Phase 3: sotalol plus antacid administered 2 hours later · Six healthy volunteers; age and sex not reported | 1.2 g | 1 day | 6 |
| Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study 2008 · magnesium supplemented group · Patients with epithelial ovarian cancer receiving cisplatin and paclitaxel chemotherapy | 1.5 g | 18 weeks | — |
| MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial 2015 · MgCaCO3 group · Adults with peritoneal dialysis | 965 mg | 90 days | — |
| Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study 1996 · MgCO3 plus half the usual dose of CaCO3 · Chronic hemodialysis patients | 465 mg | — | — |
| Therapeutic availability of iron administered orally as the ferrous gluconate together with magnesium-L-aspartate hydrochloride 1996 · Healthy volunteers: Fe-gluc plus MAH · Healthy volunteers | 15 mmol | — | — |
| A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome 2017 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS) | 200 mg | 12 weeks | 30 |
| The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes 2019 · Magnesium-zinc-calcium-vitamin D group · Women aged 18–40 with gestational diabetes mellitus, at 24–28 weeks’ gestation at diagnosis | 200 mg | 6 weeks | 30 |
| Dietary intervention with a specific micronutrient combination for the treatment of patients with cardiac arrhythmias: the impact on insulin resistance and left ventricular function 2018 · verum group · Adults aged 18–75 with cardiac arrhythmias (ventricular or supraventricular premature beats or supraventricular tachycardia); patients with cardiovascular disorders, often including hypertension or coronary artery disease | 146 mg | 6 weeks | 29 |
| Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes 2005 · group MV · Patients with type 2 diabetes; age range and sex not specified | 200 mg | 90 days | 17 |
| Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants 2009 · cinacalcet group · Healthy men and postmenopausal women aged 45–70 years | 100 mg | 11 days | 9 |
| Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants 2009 · placebo group · Healthy men and postmenopausal women aged 45–70 years | 100 mg | 11 days | 8 |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), premenopausal women · Premenopausal women, mean age 41 years; no specific condition stated | 96 mg | 12 weeks | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), postmenopausal women · Postmenopausal women, mean age 59 years; no specific condition stated | 96 mg | 12 weeks | — |